Study demonstrates that autoantibodies in systemic lupus erythematosus (SLE) patients contribute to myocardial injury by binding to and impairing stressed cardiac cells, offering insights into potential therapeutic targets.
Study demonstrates that autoantibodies in systemic lupus erythematosus (SLE) patients contribute to myocardial injury by binding to and impairing stressed cardiac cells, offering insights into potential therapeutic targets.